ADC Therapeutics Valuation
| ADCT Stock | USD 2.03 0.04 2.01% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. ADC Therapeutics owns a latest Real Value of $3.64 per share. The recent price of the firm is $2.03. Our model approximates the value of ADC Therapeutics from examining the firm fundamentals such as return on asset of -0.21, and Shares Outstanding of 96.69 M as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ADC Therapeutics' valuation include:
Price Book 2.5787 | Enterprise Value 42.7 M | Enterprise Value Ebitda (1.43) | Price Sales 2.7209 | Enterprise Value Revenue 0.6037 |
Undervalued
Today
Please note that ADC Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of ADC Therapeutics is based on 3 months time horizon. Increasing ADC Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
ADC Therapeutics' intrinsic value may or may not be the same as its current market price of 2.03, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.03 | Real 3.64 | Target 8.6 | Hype 2.05 | Naive 1.52 |
The intrinsic value of ADC Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ADC Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ADC Therapeutics SA helps investors to forecast how ADC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ADC Therapeutics more accurately as focusing exclusively on ADC Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ADC Therapeutics' intrinsic value based on its ongoing forecasts of ADC Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ADC Therapeutics' closest peers.
ADC Therapeutics Cash |
|
ADC Valuation Trend
ADC Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of ADC Therapeutics' financial worth over time. Using both ADC Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
ADC Therapeutics Total Value Analysis
ADC Therapeutics SA is presently forecasted to have valuation of 42.69 M with market capitalization of 192.41 M, debt of 124.38 M, and cash on hands of 376.78 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ADC Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
42.69 M | 192.41 M | 124.38 M | 376.78 M |
ADC Therapeutics Investor Information
About 21.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.74. ADC Therapeutics recorded a loss per share of 2.39. The entity had not issued any dividends in recent years. Based on the key indicators related to ADC Therapeutics' liquidity, profitability, solvency, and operating efficiency, ADC Therapeutics SA may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.ADC Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ADC Therapeutics has an asset utilization ratio of 19.61 percent. This implies that the Company is making $0.2 for each dollar of assets. An increasing asset utilization means that ADC Therapeutics SA is more efficient with each dollar of assets it utilizes for everyday operations.ADC Therapeutics Ownership Allocation
ADC Therapeutics secures a total of 96.69 Million outstanding shares. Over half of ADC Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.ADC Therapeutics Profitability Analysis
The company reported the previous year's revenue of 69.56 M. Net Loss for the year was (240.05 M) with profit before overhead, payroll, taxes, and interest of 35.1 M.About ADC Therapeutics Valuation
The stock valuation mechanism determines ADC Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of ADC Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of ADC Therapeutics. We calculate exposure to ADC Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ADC Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 67 M | 70.4 M | |
| Pretax Profit Margin | (2.81) | (2.95) | |
| Operating Profit Margin | (2.39) | (2.51) | |
| Net Loss | (3.45) | (3.62) | |
| Gross Profit Margin | 0.96 | 1.01 |
ADC Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as ADC Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 81.7 M |
ADC Therapeutics Current Valuation Indicators
ADC Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final ADC Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ADC Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ADC Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ADC Therapeutics' worth.Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.